Press Releases

Dr. Björn Beckmann Appointed Head of Quality Control at Rentschler Biopharma’s Laupheim Site

31 October 2023 -- Laupheim, Gemany -- Rentschler Biopharma SE, a leading global contract development and manufacturing organisation (CDMO) for biopharmaceuticals, announced that Dr. Björn Beckmann has been promoted to head of Quality Control for the Company’s site in Laupheim, Germany, effective October 1, 2023. In this new role, he is responsible for all aspects of quality control (QC), including for the development, production, release and approval of active pharmaceutical ingredients and therapeutics, and for ensuring that all quality standards and regulations are met. He also oversees the teams responsible for developing quality management strategies and preparing quality control audits by authorities and clients. In this role, he reports to Laupheim’s Site Head.

Christiane Bardroff, chief operating officer, said: “Björn has taken on increasing responsibility in his seven years at Rentschler Biopharma and has distinguished himself through his strong commitment and outstanding performance. He particularly impressed with his outstanding leadership qualities and the ability to develop and implement innovative solutions with the team. Björn is thus the perfect choice to lead the quality control and ensure that our complex and customised products continue to meet the highest standards to the full satisfaction of our clients, and thus improve the lives of patients sustainably. I am very pleased that we have been able to fill this senior position internally. This underlines that we qualify our employees sustainably and are developing them into leaders."

Dr. Beckmann has been with Rentschler Biopharma for seven years and has been promoted to positions of higher responsibility during this period. Most recently, he served as Senior Director Production Support, leading a team of approximately 150 employees in various areas, including buffer and media production, manufacturing compliance, DSP major equipment/process preparation, cleanroom maintenance, and small equipment preparation. In this role, he contributed to the improvement and advancement of all production supporting functions and was a member of the Site Leadership Team as a representative of the production. Dr. Beckmann received a PhD in technical chemistry from Leibniz Universität Hannover and an MS in pharmaceutical biotechnology from the University of Applied Sciences in Hamburg.

"Since joining Rentschler Biopharma, I have had the opportunity to grow with the company and be part of its remarkable journey. I am pleased to take on the role of Head of Quality Control in Laupheim, and I am grateful for the trust that both management and Site Head have placed in me. Achieving the highest quality isn't a matter of chance but the result of persistent effort, and it is a top priority here at Rentschler Biopharma. I am extremely proud to be a part of this global, dedicated team and look forward to working together with our partners to not only meet but exceed expectations," commented Dr. Björn Beckmann, head of Quality Control.


About Rentschler
Rentschler Biopharma is a leading contract development and manufacturing organisation (CDMO) focused exclusively on client projects. The company offers process development and manufacturing of biopharmaceuticals, including adeno-associated virus (AAV) gene therapies, as well as related consulting activities, project management and regulatory support. Rentschler Biopharma's high quality is proven by its long-standing experience and excellence as a solution partner for its clients. A high-level quality management system, a well-established operational excellence philosophy and advanced technologies ensure product quality and productivity at each development and manufacturing step. Rentschler Biopharma is a family-owned company with about 1,200 employees, headquartered in Laupheim, Germany, with a second site in Milford, MA, USA. Rentschler ATMP Ltd., located in Stevenage, UK, is dedicated to cell and gene therapies.